Expression lines
AHP-8 is designed to influence signalling involved in facial muscle contraction at the skin level.
Explore the research →COSMETIC EXPRESSION-LINE PEPTIDE
Acetyl Hexapeptide-8
A topical cosmetic peptide widely used in wrinkle-focused skincare, with particular interest around expression lines and smoother-looking skin.
Expression linesWrinklesSkin texture
Some human cosmetic evidence, often in combination formulationsClinical studies report improvements in wrinkle appearance with products containing acetyl hexapeptide-8, although formulation effects make it difficult to attribute every result to the peptide alone.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Acetyl Hexapeptide-8?
Acetyl Hexapeptide-8 is marketed around a simple cosmetic idea: soften the appearance of expression lines without an injection. That has made it a familiar skincare peptide, with human studies suggesting wrinkle improvement in some formulations.
Fine lines & texture
Repeated topical use is associated with smoother-looking skin in some studies.
Explore the research →Topical alternative
Its appeal comes from a non-invasive topical approach rather than systemic peptide administration.
Explore the research →Combination skincare
AHP-8 is frequently paired with humectants, acids and other peptides.
Explore the research →THE SCIENCE BIT
A proposed influence on the nerve's release machinery.
Acetyl hexapeptide-8 is patterned from part of SNAP-25, a protein involved in releasing neurotransmitters. Its proposed mechanism concerns SNARE machinery, which helps tiny vesicles fuse with a cell membrane.
That explains the expression-line research, but skin penetration and delivery to nerve endings remain important questions. A topical cosmetic peptide should not be presented as equivalent to injected botulinum toxin.
See the studies & trials →- SNAP-25-inspired
- The peptide's design
- SNARE machinery
- Vesicle-fusion research
- Topical delivery
- Penetration matters
How this connects to the research
A proposed laboratory mechanism with formulation-dependent cosmetic evidence.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Acetyl Hexapeptide-8 connects with the body
These are the tissues and biological systems behind the interest in Acetyl Hexapeptide-8.
- Skin surface
- Cosmetic application.
- Expression-line areas
- Clinical appearance studies.
- Nerve endings
- The proposed target context.
The research behind the interest
Expression lines
AHP-8 is designed to influence signalling involved in facial muscle contraction at the skin level.
Clinical formulations containing AHP-8 have shown improvements in dynamic wrinkle appearance.
Human cosmetic evidenceExplore the studies →Fine lines & texture
Repeated topical use is associated with smoother-looking skin in some studies.
Many trials test multi-ingredient products, so the peptide's independent contribution can be uncertain.
Developing human evidenceExplore the studies →Topical alternative
Its appeal comes from a non-invasive topical approach rather than systemic peptide administration.
Effects should not be described as equivalent to botulinum toxin treatment.
Cosmetic evidenceExplore the studies →Combination skincare
AHP-8 is frequently paired with humectants, acids and other peptides.
Combination studies support the finished formula, not necessarily AHP-8 alone.
Formulation-dependent evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableMicroneedle patch with acetyl hexapeptide-8 for wrinkles ↗
52 Korean women
Topical dissolving microneedle patch29 days
The study assessed periorbital and nasolabial wrinkle changes with AHP-8-containing patches.
Serum containing acetyl hexapeptide-8 and other actives ↗
Two clinical cohorts of 50 and 42 participants
TopicalUp to 12 weeks
The multi-ingredient serum improved static and dynamic wrinkle scores and several skin-quality measures.
Because the formula contained several actives, the result cannot be assigned to AHP-8 alone.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceDeveloping
3/5 evidence depth
Human cosmetic studies exist, including controlled patch and serum studies.
✓
Clinical efficacyDeveloping
3/5 evidence depth
Wrinkle improvement is reported, but many formulations contain multiple active ingredients.
◇
Safety evidenceStrong
4/5 evidence depth
Topical tolerability is better characterised than systemic use.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Mechanistic cosmetic research supports the signalling concept.
HOW TO READ THESE SCORESDeveloping preclinical evidence · developing human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Acetyl Hexapeptide-8 research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Expression lines
RESEARCH AREA 02Wrinkles
RESEARCH AREA 03Skin texture
RESEARCH AREA 04Topical skincare
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Acetyl Hexapeptide-8
Interest centres on expression lines, fine wrinkles and non-invasive skincare.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Softening expression lines
Interest focuses on forehead, eye-area or other lines associated with facial movement. The appeal is a topical cosmetic option, while the proposed mechanism does not establish an injected-toxin-like effect.
- What makes a report informative
- Comparable photographs at rest and during the same expression.
- What can muddy the picture
- Changing facial expression or lighting can create an apparent improvement.
Smoother fine wrinkles
People also want subtler surface lines and a smoother appearance. A finished formula may affect hydration as well as any peptide-related action, so the ingredient cannot automatically receive all the credit.
- What makes a report informative
- Appearance under similar conditions and the full formulation.
- What can muddy the picture
- Moisturising effects and other active ingredients are major confounders.
A comfortable addition to a skincare routine
Interest includes finding a tolerable product that fits alongside other skincare. That practical experience matters, but ingredient presence alone does not tell someone how much reaches a proposed target.
- What makes a report informative
- Tolerability and consistent cosmetic results over time.
- What can muddy the picture
- Skin penetration and formulation are important; topical use is not equivalent to botulinum toxin.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Expression lines
Clinical formulations containing AHP-8 have shown improvements in dynamic wrinkle appearance.
Evidence context: Human cosmetic evidence
Fine lines & texture
Many trials test multi-ingredient products, so the peptide's independent contribution can be uncertain.
Evidence context: Developing human evidence
Topical alternative
Effects should not be described as equivalent to botulinum toxin treatment.
Evidence context: Cosmetic evidence
Combination skincare
Combination studies support the finished formula, not necessarily AHP-8 alone.
Evidence context: Formulation-dependent evidence
The biological rationale
Acetyl hexapeptide-8 is patterned from part of SNAP-25, a protein involved in releasing neurotransmitters. Its proposed mechanism concerns SNARE machinery, which helps tiny vesicles fuse with a cell membrane.
That explains the expression-line research, but skin penetration and delivery to nerve endings remain important questions. A topical cosmetic peptide should not be presented as equivalent to injected botulinum toxin.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Evidence concerns topical cosmetic formulations; there is no reason to translate this into an injectable dosing model.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Weekly topical patch study reminder
Human cosmetic study · product-specificThe study reports weekly use of its specific patch and assessment at day 29, with a four-hour application. One entry means one application; no peptide mass is supplied. The result cannot be transferred to ordinary serums or injected products.
Form and route: Topical CLHA/HA microneedle patch containing acetyl hexapeptide-8
| Calendar stage | Amount each time |
|---|---|
| Days 1–28 | 1 application |
Frequency: Every 7 days · 1 entry per scheduled day.
This copy uses four weekly reminders in a 28-day planning window, rather than inferring an additional application on the day-29 assessment. Edit the dates for the specific product. Applications do not deduct milligram stock.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Topical formulation, not injectable peptide therapy
What the current evidence saysEvidence is tied to topical cosmetic products. Irritation or sensitivity can come from the full formulation, and clinical results from one formula do not establish all products as equivalent.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Bibliographic recordMicroneedle patch with acetyl hexapeptide-8 for wrinklesPubMed ↗Original publicationSerum containing acetyl hexapeptide-8 and other activesJournal / DOI ↗Bibliographic recordSerum containing acetyl hexapeptide-8 and other activesPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesDrugs@FDA ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
Acetyl Hexapeptide-8 is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.